Branded

Upsher-Smith was named Best Overall Branded Pharmaceutical Product Manufacturer with less than $300 million in sales.

Endo currently expects to launch the differentiated branded product in the United States in 2025.

The topical cream is for the treatment of bumps and blemishes (inflammatory lesions) of rosacea in adults. 

Evrysdi is designed to treat SMA by increasing and sustaining the production of the survival motor neuron protein in the central nervous system and peripheral tissues.

​​​​​​​Tibsovo is the first therapy targeting cancer metabolism approved in combination with azacitidine for patients with newly diagnosed IDH1-mutated acute myeloid leukemia.

Mounjaro is administered by injection under the skin once weekly, with the dose adjusted as tolerated to meet blood sugar goals.

​​​​​​​Qelbree is the first novel, nonstimulant option for adults with ADHD in 20 years, the company said.

​​​​​​​Ready-to-administer calcium gluconate in non-PVC, non-DEHP containers is designed to promote safety and convenience.

Veklury (remdesivir) is the first and only approved treatment for pediatric patients under age 12 years old with COVID-19.

With a ​​​​​​​prescription from their healthcare provider, Rite Aid customers have increased access to Paxlovid and Molnupiravir.

Ztal​​​​​​​my is the first and only FDA-approved treatment for seizures associated with CDKL5 deficiency disorder in patients aged 2 years old and older, the company said.

Triumeq, the first dispersible single-tablet regimen containing dolutegravir, increases age-appropriate treatment options for children living with HIV, the company said.